Cetirizine vs Diphenhydramine for Multiple Sclerosis

This trial examines how well individuals with multiple sclerosis (MS) tolerate two common allergy medicines, cetirizine and diphenhydramine, before receiving certain MS treatments. The researchers aim to determine which medicine is safer and more effective at preventing reactions during these treatments. Individuals with MS who are about to start or are currently receiving treatments like ocrelizumab, ublituximab, or rituximab may find this trial relevant. Participants will take either cetirizine or diphenhydramine before their regular treatment to assess its effectiveness. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to important research that could enhance the safety of MS treatments.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that both cetirizine and diphenhydramine are generally safe for use. Cetirizine does not increase the risk of reactions during infusions compared to diphenhydramine, making it a safe option for pre-treatment. Various studies have tested cetirizine, reporting few major issues. However, cetirizine might affect memory and concentration, which could concern individuals with multiple sclerosis (MS).

Diphenhydramine is often used to prevent allergic reactions during treatments and is known to reduce the risk of these reactions. However, it may cause more side effects, especially in children and older adults, such as drowsiness and confusion.

Researchers are excited about using cetirizine and diphenhydramine for multiple sclerosis because these medications might offer a new approach to managing infusion-related reactions during anti-CD20 therapy. Unlike traditional treatments that focus directly on modifying the immune system, cetirizine and diphenhydramine are antihistamines that work by blocking histamine action, potentially reducing allergic reactions and improving patient comfort during infusions. This could make the infusion process smoother and more tolerable, providing an added layer of care for patients undergoing standard multiple sclerosis treatments.

This trial will compare Cetirizine and Diphenhydramine as pre-medications for anti-CD20 infusion therapy in multiple sclerosis (MS) patients. Research has shown that cetirizine does not increase the risk of reactions during infusions compared to diphenhydramine, suggesting it is a safe choice. Participants in the Cetirizine Group will receive cetirizine, which causes fewer drowsiness issues in MS patients taking ocrelizumab, another anti-CD20 drug. However, cetirizine alone has not been very effective in managing flu-like symptoms related to MS. Participants in the Diphenhydramine Group will receive diphenhydramine, often used to prevent allergic reactions during infusions, but it can cause drowsiness. These findings help clarify how each medication might work as a pre-treatment for MS patients.¹⁶⁷⁸⁹